North America Viral Vector Manufacturing Market

North America Viral Vector Manufacturing Market Size (2023 to 2028)

The North American market size for viral vector manufacturing is estimated to be worth USD 527.92 million by 2028 from USD 207.10 million in 2023, growing at a CAGR of 20.58% from 2023 to 2028.

The growing prevalence of chronic diseases such as cancer and chronic infections in North American countries is one of the key factors propelling the growth of the North American viral vector manufacturing market. An estimated 1.9 million new cancer cases were reported in the U.S. in 2021. The cancer patient population is expected to rise in the coming years due to various factors such as lifestyle, hormonal changes, increasing consumption of alcohol and smoking, and genetic issues. The incidence of lung, skin, colon and throat cancer is high compared to the other cancer types. To combat these diseases, viral vectors have emerged as crucial tools in the manufacturing of tumor antigens and gene delivery, enabling the body to effectively fight against cancer cells. The viral vectors play a key role in the manufacturing process of cell therapies for cancer patients. Viral vectors enable the manipulation and enhancement of T-cells, ultimately enhancing their ability to recognize and eliminate cancerous cells.

The growing research and development efforts in the field of cell and gene therapy in North America further fuel the growth rate of the North American viral vector manufacturing market. Researchers are actively engaged in advancing viral vector approaches to minimize antigen rejection among patients. Moreover, viral vectors are instrumental in vaccine development by effectively neutralizing viruses that infect cells. Leveraging viral vectors offers numerous advantages, including enhanced gene transduction efficiency, precise gene delivery to target cells, and bolstered immune responses.

The notable advancements in viral vector manufacturing contribute to the growth of the North American viral vector manufacturing market. Over the years, the manufacturing of viral vectors has necessitated adherence to stringent biological safety levels. However, with the emergence of advanced devices specifically designed for viral vector manufacturing, the North American market has experienced significant progress. These state-of-the-art devices have facilitated streamlined production processes and enhanced safety measures, thereby contributing to regional market growth.

The high cost associated with gene therapies hampers the growth of the North American viral vector manufacturing market as it limits patient access and affordability. The incorrect placement of genes in the DNA location further hinders the growth potential, as it undermines the effectiveness and safety of gene therapies. The scarcity of skilled professionals proficient in gene therapy techniques poses a challenge, as their expertise is crucial for successful treatment outcomes. Furthermore, the lack of proper infrastructure facilities adds to the hurdles, hindering the seamless delivery of gene therapies. Alongside this, the high cost of procedures exacerbates the situation, limiting patient adoption and posing financial burdens.

This report on the North American viral vector manufacturing market has been segmented and sub-segmented into the following categories.

By Type:

• Adeno-Associated Viral Vectors
• Retroviral Vectors
• Adenoviral Vectors

By Application:

• Gene Therapy
• Vaccinology Development

By Disease:

• Cancers
• Genetic Disorders
• Infectious diseases
• Other Diseases

By Country:

• The United States
• Canada
• Rest of North America

North America accounted for the largest share of the global market in 2022 and is expected to continue the dominating trend throughout the forecast period.

The U.S. had the major share of the North American market in 2022, followed by Canada and the same pattern is predicted to continue during the forecast period. The growing number of clinical trials and robust research and development landscape in the U.S. majorly propel the U.S. market growth. The availability of skilled professionals in the U.S. and laboratory infrastructure further contribute to the dominance of the U.S. market in the North American region. The growing number of FDA approvals for viral vector manufacturing facilities and the presence of several market participants favors the regional market growth.

The Canadian market is predicted to hold a considerable share of the North American market during the forecast period.

KEY MARKET PLAYERS:

FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Cobra Biologics, Catalent Inc., Wuxi Biologics, Takara Bio Inc., Waisman Biomanufacturing, Genezen laboratories, Batavia Biosciences, Miltenyi Biotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, and Audentes Therapeutics are some of the noteworthy companies operating in the North America viral vector manufacturing market profiled in this report.